Clinical Trial RESULTS

Research Sponsor: AstraZeneca
Drug Studied: Anifrolumab
National Clinical Trial #: NCT02601625
Protocol #: D3461C00006
Study Date: November 2015 to May 2016
Short Study Title: A study in healthy participants to see how anifrolumab acts in the body and how safe it is to take

Thank you!

As a clinical study participant, you belong to a large community of participants around the world. You help researchers answer important health questions and discover new medical treatments.

Thank you for taking part in the clinical study for the drug anifrolumab. This drug is being developed to treat an autoimmune disease called lupus, or lupus-related swelling in the kidneys. You and all of the participants helped researchers learn how anifrolumab acts in the body and if the drug causes medical problems.

AstraZeneca, the sponsor of this study, thanks you for your help and thinks it is important for you to know the results of your study. An independent nonprofit organization called CISCRP prepared this summary of the study results for you with the help of a medical writing organization. We hope it helps you understand and feel proud of your important role in medical research. If you have questions about the results, please speak with the doctor or staff at your study site.